Compare ZUMZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | ZNTL |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.2M | 289.0M |
| IPO Year | 2005 | 2020 |
| Metric | ZUMZ | ZNTL |
|---|---|---|
| Price | $13.95 | $3.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $6.60 |
| AVG Volume (30 Days) | 304.8K | ★ 763.7K |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $929,057,000.00 | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $13.07 | $1.21 |
| 52 Week High | $31.70 | $6.95 |
| Indicator | ZUMZ | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 27.05 |
| Support Level | N/A | $2.09 |
| Resistance Level | $18.87 | $3.30 |
| Average True Range (ATR) | 0.68 | 0.22 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 16.90 | 3.35 |
Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.